Lipoprotein-associated Phospholipase A2 in Coronary Artery Disease / Yannis Dimitroglou, Athanasios Sakalidis, Andreas Mavroudis, Charalambos Kalantzis, Angeliki Valatsou, Ioannis Andrikou, Angela Christofi, Emmanouil Mantzouranis, Ioannis Kachrimanidis, Evellina Bei, Emilia Lazarou, Costas Tsioufis, Dimitris Tousoulis, George Lazaros
Coronary artery disease (CAD) is the leading cause of morbidity and mortality in western societies. Therefore the identification of novel biomarkers to be used as diagnostic or therapeutic targets is of significant scientific interest. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is one such protein shown to be involved in endothelial dysfunction, vascular inflammation and atherogenesis. Several epidemiological studies have associated high Lp-PLA2 activity with an increased risk for CAD even when other CAD risk factors or inflammation markers were included in the multivariate analysis. These findings were strengthened by the results of relevant meta-analyses. However, randomized trials failed to establish Lp-PLA2 as a therapeutic target. Specifically, pharmaceutical inhibition of Lp-PLA2 when compared to the placebo failed to demonstrate a significant association with improved prognosis of patients with stable CAD or after an acute coronary syndrome (ACS). This review focuses on the available data that have investigated the potential role of Lp- PLA2 as a biomarker for CAD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Current topics in medicinal chemistry - 22(2022), 28, Seite 11 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dimitroglou, Yannis [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (11 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL01117708X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL01117708X | ||
| 003 | DE-627 | ||
| 005 | 20231128080241.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230613s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL01117708X | ||
| 035 | |a (KFL)prod_DARH_.1265C57318A289E4FAD67A3B9EBE4BF9475384B0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Dimitroglou, Yannis |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lipoprotein-associated Phospholipase A2 in Coronary Artery Disease |c Yannis Dimitroglou, Athanasios Sakalidis, Andreas Mavroudis, Charalambos Kalantzis, Angeliki Valatsou, Ioannis Andrikou, Angela Christofi, Emmanouil Mantzouranis, Ioannis Kachrimanidis, Evellina Bei, Emilia Lazarou, Costas Tsioufis, Dimitris Tousoulis, George Lazaros |
| 264 | 1 | |c 2022 | |
| 300 | |a 1 Online-Ressource (11 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Coronary artery disease (CAD) is the leading cause of morbidity and mortality in western societies. Therefore the identification of novel biomarkers to be used as diagnostic or therapeutic targets is of significant scientific interest. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is one such protein shown to be involved in endothelial dysfunction, vascular inflammation and atherogenesis. Several epidemiological studies have associated high Lp-PLA2 activity with an increased risk for CAD even when other CAD risk factors or inflammation markers were included in the multivariate analysis. These findings were strengthened by the results of relevant meta-analyses. However, randomized trials failed to establish Lp-PLA2 as a therapeutic target. Specifically, pharmaceutical inhibition of Lp-PLA2 when compared to the placebo failed to demonstrate a significant association with improved prognosis of patients with stable CAD or after an acute coronary syndrome (ACS). This review focuses on the available data that have investigated the potential role of Lp- PLA2 as a biomarker for CAD | ||
| 700 | 1 | |a Sakalidis, Athanasios |e verfasserin |4 aut | |
| 700 | 1 | |a Mavroudis, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Kalantzis, Charalambos |e verfasserin |4 aut | |
| 700 | 1 | |a Valatsou, Angeliki |e verfasserin |4 aut | |
| 700 | 1 | |a Andrikou, Ioannis |e verfasserin |4 aut | |
| 700 | 1 | |a Christofi, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Mantzouranis, Emmanouil |e verfasserin |4 aut | |
| 700 | 1 | |a Kachrimanidis, Ioannis |e verfasserin |4 aut | |
| 700 | 1 | |a Bei, Evellina |e verfasserin |4 aut | |
| 700 | 1 | |a Lazarou, Emilia |e verfasserin |4 aut | |
| 700 | 1 | |a Tsioufis, Costas |e verfasserin |4 aut | |
| 700 | 1 | |a Tousoulis, Dimitris |e verfasserin |4 aut | |
| 700 | 1 | |a Lazaros, George |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current topics in medicinal chemistry |d Spring House, Pa. : [Verlag nicht ermittelbar], 2001 |g 22(2022), 28, Seite 11 |h Online-Ressource |w (DE-627)KFL000006378 |w (DE-600)2096030-X |w (DE-576)273886622 |x 1873-4294 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:28 |g pages:11 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1568-0266&volume=22&issue=28&spage=2344 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_DARH_03 | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 28 |h 11 | ||